Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 7Neoplasms 4Advanced Cancer 4Lymphoma, Non-Hodgkin 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Hodgkin Disease 2Various Advanced Cancer 1Uveal Melanoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Site 1Microsatellite Unstable Colorectal Cancer 1Melanoma, Cutaneous Malignant 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1Advanced Solid Tumors 1

Interventions

Pemetrexed 10Carboplatin 8pembrolizumab 7Cisplatin 7130-nm albumin-bound paclitaxel 6Paclitaxel 5Nivolumab 5Gemcitabine 5ribociclib 4palbociclib 4napabucasin 4durvalumab 4Fulvestrant 4Bevacizumab 4osimertinib 3abemaciclib 3Mitomycin 3Irinotecan 3Fluorouracil 3Drug Therapy 3Anastrozole 3Albumin-Bound Paclitaxel 3AZD9833 3selpercatinib 2pralsetinib 2patritumab 2ficlatuzumab 2exemestane 2atezolizumab 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms by Site × relatlimab × Clear all
NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
1,482 enrolled 56 charts
Tumor-Agnostic

Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡